Skip to main content

Featured

Weekly Market Snapshot: Geopolitical Fog Meets Earnings Season as Markets Grind Higher

Week ending April 24, 2026 | Canadian Money Brief – moneysavings.ca Markets this week found themselves caught between two powerful forces: a roaring U.S. earnings season pushing stocks to fresh records, and a simmering Middle East conflict keeping oil elevated and investor nerves frayed. For Canadians, that makes for a complicated but important picture heading into the last week of April. TSX Composite: Stuck in the Mud The S&P/TSX Composite spent the week trading in a tight band near the 34,000 mark, unable to mount a meaningful rally. Tuesday delivered a sharp blow — the index plunged over 550 points to close at 33,808 as U.S.-Iran ceasefire talks collapsed after U.S. Vice President JD Vance abruptly cancelled his Pakistan trip, where he was set to lead negotiations. Wednesday brought a partial recovery, with the TSX adding roughly 0.4% to close at 33,955 , helped by gains in energy and mining stocks following President Trump's announcement of an indefinite ceasefire ex...
Post a Comment
Read more

article

Labels

Stock Futures Steady as Investors Await Fresh Jobs Data

U.S. stock futures were little changed on Thursday as Wall Street attempted to recover from recent declines. Futures tied to the S&P 500 were flat, while Nasdaq futures rose slightly. Dow Jones Industrial Average futures fell marginally.

Labor Market Update: Today’s spotlight is on the release of the report on initial weekly jobless claims. A positive number could reassure traders about the state of the jobs market, while a negative one may introduce more turbulence. Last week’s sluggish non-farm payrolls update was one of the catalysts for recent declines.

Individual Movers:

  • Nvidia (NVDA): The AI giant’s stock is in focus after a back-and-forth day left it down another 5%.
  • Eli Lilly (LLY): The company’s stock soared over 10% in premarket trading after boosting its annual revenue and profit forecasts on strong weight-loss drug sales.


Labels:

Comments

Post a Comment